CN106178063A - A kind of without immunologic rejection adhesive bandage - Google Patents
A kind of without immunologic rejection adhesive bandage Download PDFInfo
- Publication number
- CN106178063A CN106178063A CN201610665180.4A CN201610665180A CN106178063A CN 106178063 A CN106178063 A CN 106178063A CN 201610665180 A CN201610665180 A CN 201610665180A CN 106178063 A CN106178063 A CN 106178063A
- Authority
- CN
- China
- Prior art keywords
- poly
- acid
- fiber
- growth factor
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000853 adhesive Substances 0.000 title claims abstract description 22
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 22
- 230000001900 immune effect Effects 0.000 title claims abstract description 10
- 230000037314 wound repair Effects 0.000 claims abstract description 30
- 239000010410 layer Substances 0.000 claims abstract description 11
- 239000012790 adhesive layer Substances 0.000 claims abstract description 3
- 239000000835 fiber Substances 0.000 claims description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 238000004132 cross linking Methods 0.000 claims description 25
- 239000000725 suspension Substances 0.000 claims description 20
- 102000008186 Collagen Human genes 0.000 claims description 19
- 108010035532 Collagen Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 239000003431 cross linking reagent Substances 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 11
- 239000003102 growth factor Substances 0.000 claims description 11
- 238000007598 dipping method Methods 0.000 claims description 10
- 239000004088 foaming agent Substances 0.000 claims description 10
- -1 poly-(anhydride) Polymers 0.000 claims description 10
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 230000010261 cell growth Effects 0.000 claims description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 8
- 102000013275 Somatomedins Human genes 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 229920000954 Polyglycolide Polymers 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 5
- 239000001095 magnesium carbonate Substances 0.000 claims description 5
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 5
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 5
- 230000005070 ripening Effects 0.000 claims description 5
- 238000007711 solidification Methods 0.000 claims description 5
- 230000008023 solidification Effects 0.000 claims description 5
- 238000000352 supercritical drying Methods 0.000 claims description 5
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 4
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims description 4
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 150000004781 alginic acids Chemical class 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 4
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 229920002085 Dialdehyde starch Polymers 0.000 claims description 3
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 238000003763 carbonization Methods 0.000 claims description 3
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 claims description 3
- 229910000071 diazene Inorganic materials 0.000 claims description 3
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000000122 growth hormone Substances 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims description 2
- OPPFIPBEHRZBOT-UHFFFAOYSA-N 1,1-bis(oxiran-2-ylmethoxy)propan-1-ol Chemical compound C1OC1COC(O)(CC)OCC1CO1 OPPFIPBEHRZBOT-UHFFFAOYSA-N 0.000 claims description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 102100022987 Angiogenin Human genes 0.000 claims description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 2
- 229920000049 Carbon (fiber) Polymers 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims description 2
- QXKAIJAYHKCRRA-JJYYJPOSSA-N D-arabinonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(O)=O QXKAIJAYHKCRRA-JJYYJPOSSA-N 0.000 claims description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 2
- 108010022355 Fibroins Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920001503 Glucan Polymers 0.000 claims description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002527 Glycogen Polymers 0.000 claims description 2
- 102000000589 Interleukin-1 Human genes 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 241000219433 Myrica Species 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 108010072788 angiogenin Proteins 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 230000034127 bone morphogenesis Effects 0.000 claims description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 2
- 239000004917 carbon fiber Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 230000003399 chemotactic effect Effects 0.000 claims description 2
- 238000005660 chlorination reaction Methods 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 229960005188 collagen Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 125000005442 diisocyanate group Chemical group 0.000 claims description 2
- YIOJGTBNHQAVBO-UHFFFAOYSA-N dimethyl-bis(prop-2-enyl)azanium Chemical compound C=CC[N+](C)(C)CC=C YIOJGTBNHQAVBO-UHFFFAOYSA-N 0.000 claims description 2
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 229940096919 glycogen Drugs 0.000 claims description 2
- 150000002337 glycosamines Chemical class 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 150000003949 imides Chemical class 0.000 claims description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 229920006209 poly(L-lactide-co-D,L-lactide) Polymers 0.000 claims description 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 229960002901 sodium glycerophosphate Drugs 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 210000000051 wattle Anatomy 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
- 239000004926 polymethyl methacrylate Substances 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 description 21
- 206010052428 Wound Diseases 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 12
- 229960004756 ethanol Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 6
- 229920001872 Spider silk Polymers 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 238000009987 spinning Methods 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010062575 Muscle contracture Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000512 collagen gel Substances 0.000 description 3
- 208000006111 contracture Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000000515 collagen sponge Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 101150014221 Son gene Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 238000010041 electrostatic spinning Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 210000000835 hypertrophic cicatrix Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
Abstract
It is a kind of without immunologic rejection adhesive bandage, it is characterised in that: adhesive bandage includes fibrous base layer, adhesive layer and wound repair dressing layer.
Description
Technical field
The present invention relates to a kind of without immunologic rejection adhesive bandage, belong to medical aid field.
Background technology
Wound surface is that normal skin (tissue) is caused injury in the external world factor such as surgical operation, external force, heat, electric current, chemical substance, low
The lower infringements caused of effect such as temperature and body intrinsic factor such as local blood supply obstacle.It is often accompanied by the broken of skin integrity
The loss of bad and a certain amount of normal structure, meanwhile, the normal function of skin is impaired.Also referred to as wound or wound.Wound surface is repaiied
Multiple both wound repair.Wound repair is most important, the most basic problem that wound, burns unit or even whole medical circle are faced
One of, but really it being carried out system and in-depth study as an independent problem, recent 20 years just causes people
The attention of height.On the one hand, many basic problems of wound repair the most really do not achieve a solution, on the other hand, modern
The development of medical science, particularly molecular biology proposes many new problems, even some important concepts to wound repair again
Also constantly updating and development.As traditional dressing (gauze) only plays the effect of simple flap coverage, and present, develop dressing
Concept there occurs that flap coverage is not only wanted in basic change, i.e. dressing, also should have the function promoting tissue repair, i.e. institute
Meaning " activity dressing " or " revolutionary dressing ".Secondly, along with the improvement day by day of living standards of the people, to the requirement of quality of life also
More and more higher, thus the chronic skin ulcer the most less paid attention to for people is the most increasingly paid attention to by people with scar prevention.
Therefore, paying attention to further wound repair research is learned needs, be also social development to after certain phase to medical science and
The new demand that biology proposes.
Abroad attaching great importance to wound repair, its basic research is deeply to cell, molecule and gene level.The seventies with
Come, owing to can effectively obtain a large amount of cytokine and for zoopery so that with somatomedin and wound repair relation
Tissue repair research for breach is abroad walked in prostatitis, and has thus driven the development of whole wound repair.Through nearly 20
Year effort, the cytology of tissue repair, extracellular matrix and collagenic supersession, somatomedin promote (pressing down) wound repair mechanism,
The pathophysiological features of chronic difficult healing ulcer and promoting healing method, the origin cause of formation and the control of hypertrophic cicatrix, the grinding of active dressing
The aspects such as system and gene therapy achieve the progress attracted people's attention, and many Basic Research Results have started to be applied to clinic.
We are continued for constantly in the national research about wound repair, and obtain in fields such as burn wound's reparations
Encouraging success.But generally, China's holistic approach in this field still lags behind western developed country, and basic research falls again
After in clinical treatment.Owing to wound repair is a system engineering, relate to many medical science necks such as surgery, the traumatology department, burn, shaping
Territory, and many with biochemistry, biology, molecular biology, biomechanics and biomaterial etc. basic and applied science
Have and contact widely.Therefore, if it not being carried out interdiscipline, multi-disciplinary tackling key problem as a great problem, it is clear that
It is difficult to make a breakthrough.China famous academician of the Chinese Academy of Engineering Sheng Zhiyong professor, that Beijing 304 hospital pays professor dogface etc. is large quantities of
Medical science celebrity, began to as far back as 2003 deliver a large amount of paper or monograph successively, and proposes " the modern times to be made full use of
The achievement of High biotechnology, explores normal and the secret of tissue repair generation out of control from cell, molecule with gene level, finds
Promote restorative procedure reliably, accelerate exploitation and the application of new product." viewpoint.At present, Commercialization application in clinical
Skin wound covering has: epidermal sheet, acellular dermal matrix, collagen sponge membrane, collagen gel film etc..1. epidermis
Cell patch: this diaphragm (KC) shortcoming is to take the skin biopsy specimen of patient, needs the time in 2-3 week, lacks
Dermal components, diaphragm belittle frangible [O ' ConnerNE, Malliken JB, Bankaclilegcls, et al.Grafting of
burns with cultured epitheliunt prepared from autologous epidermal cells[J]
.Lancet, 1981,1:75-78].2. acellular dermal matrix: its shortcoming is possible to have biography containing the antigenic substance of non-Ex-all
Catching an illness the danger of poison, and material hole connectivity is poor.3. collagen sponge membrane: such as Chinese patent 94118836.1 He
01134743.0, its shortcoming is not contain the raw sub-factor of cell in material, and poor mechanical property, it is impossible to infection；China is specially
Profit 200510022581.X, although being directly added into somatomedin in material, but does not introduces microsphere sustained-release technology, and somatomedin is easy
Lose biological activity.4. collagen gel: such as Chinese patent CN02117585.3 and CN03130382.X, shortcoming is production process
Complexity, collagen gel can shrink about 80%, resists degraded by collagenase ability, is subject to virus and infects anti-with immunologic rejection
Should, fragility is big, operation technique difficulty.
Summary of the invention
The present invention is directed to the deficiencies in the prior art provide a kind of have extremely low without immunologic rejection or immunologic rejection effect, answer
With in extensive range, the adhesive bandage of wound repair excellent.The present invention is achieved through the following technical solutions above-mentioned purpose.
It is a kind of without immunologic rejection adhesive bandage, it is characterised in that: adhesive bandage includes fibrous base layer, adhesive layer and wound repair
Dressing layer.It is characterized in that comprising the steps:
(1) three-dimensional fiber sill is manufactured
The first step: be dispersed in by Biodegradable fibers in water or ethanol, forms homogeneous suspension；In described suspension, fiber
Mass fraction be 1-10%；Second step: described suspension is carried out at 15-36 DEG C ripening 8-15h, makes suspension shape
Become coagulated mass；3rd step: use supercritical drying drying method to remove water or the ethanol of solidification in described coagulated mass, form fiber and interlock
Material；4th step: the material that interlocked by fiber carries out 1-5h thermal crosslinking treatment, it is thus achieved that the three-dimensional fiber that fiber cross-point is adhesively fixed
Sill；
Biodegradable fibers is selected from: polylactic acid, polycaprolactone, PGA, polyurethane, polyvinyl alcohol or fibroin, elastic force
The fiber that one or more materials of the peptide polymer of albumen mimicry, alginic acid are made.
(2) porous process is carried out
The three-dimensional fiber sill that step (1) obtains is immersed in water, then adds cause porous combination thing, treatment temperature 20
～60 DEG C, the time is 10～60min.
Described cause porous combination thing is: magnesium carbonate, foaming agent and biocompatible adhesive, wherein said foaming agent comprises phosphorus
The mol ratio that hydrochlorate and hydrophosphate, this phosphate and hydrophosphate exist in described compositions is 1:3-1:15, this combination
React during thing hydration thus produce the carbon dioxide as gas component, wherein discharge described gas component from described compositions
Produce the porosity of at least 8% in the composition；
(3) dipping collagen protein
The three-dimensional fiber sill dipping after porous the being processed collagen protein hydrosol containing cell growth factor, then does
Dry, cell growth factor content is 1-10wt%, and the content of collagen protein is 130 1500IU/mL；
(4) crosslinking curing
Carrying out crosslinking curing after Gan Zaoing, wherein, described cross-linking agent is selected from 1-ethyl-3-(3-DimethylAminopropyl)-carbonization
Diimine, glutaraldehyde, dialdehyde starch, diglycidyl ether of ethylene glycol, propanetriol-diglycidyl-ether, myrica extract, wattle extract,
Any one in 1,6-own diisocyanate；After crosslinking curing terminates, obtain wound repair dressing；
(5) adhesive bandage is manufactured
Wound repair dressing is bonded in fibrous base layer.
In wherein said cross-linking agent solution, the content concn of cross-linking agent is preferably 0.01～0.05mol/L, more preferably
0.03mol/L；The time of described crosslinking curing is preferably 5～12h, more preferably 8～9h.
Described cytokine is to go back to the nest cell or chemotactic or cell break up the factor worked, and these factors are selected from
Cell directional migrate the factor (SDF-1), epidermal growth factor (EGF), fibroblast growth factor (FGF), interleukin I L-3,
Angiogenin binding factor (ECM), transforminggrowthfactor-α (TGF-α), platelet-derived somatomedin (PDGF) or thin
Born of the same parents' directional migration factor, insulin-like growth factor, bone morphogenetic protein, bone morphogenesis protein-2, vascular endothelial growth factor
Son, Connective Tissue Growth Factor, basic fibroblast growth factor, osteopontin, growth hormones (such as: growth hormone)
Deng cytotaxis and adhesion factor
Described biocompatible adhesive also includes: nucleic acid, carbohydrate, protein, polypeptide, poly-('alpha '-hydroxy acids), poly-
(lactone), poly-(aminoacid), poly-(anhydride), poly-(ortho esters), poly-(anhydride-CO-acid imide), poly-(orthocarbonic ester), poly-(α-
Hydroxyalkanoate), poly-(phosphate ester), poly-(L-lactide) (PLLA), PLA (PDLLA), PGA
(PGA), poly-(lactide-CO-Acetic acid, hydroxy-, bimol. cyclic ester) (PLGA), poly-(L-lactide-CO-D, L-lactide), poly-(D, L-lactide-
CO-propylene carbonate), poly butyric ester (PHB), polycarboxylic acids, poly-(hydrochloric acid allylamine), poly-(chlorination diallyl dimethyl
Ammonium), poly-(ethylenimine), poly-fumaric acid propylene glycol ester, polyvinyl alcohol, polyvinyl pyrrolidone, polyethylene, poly-methyl
Acrylic acid methyl ester., carbon fiber, Polyethylene Glycol, poly(ethylene oxide)polymers, poly-(vinyl alcohol), and PVP, epoxy second
Alkane-CO-propylene oxide block copolymer, poly-(ethylene glycol terephthalate), polyamide, and their copolymer.
Described biocompatible adhesive is selected from: alginic acid, arabic acid, guar gum, xanthan gum, gelatin, chitin, de-second
Acyl chitin, acetic acid chitosan, lactic acid chitosan, chondroitin sulfate, the deacetylated shell of N, O-carboxymethyl is many
Sugar, glucosan, Fibrin Glue, glycerol, hyaluronic acid, hyaluronate sodium, cellulose, glycosamine, Dan Baiduotang proteoglycan PG, starch, breast
Acid, PEO-PPO, sodium glycerophosphate, collagen, glycogen, keratin, silk, and their mixture.
Compared with prior art, there is advantages that
(1) introducing of pore compositions makes dressing have higher and evenly hole than conventional wound-surface plaster, strengthens dressing and exists
Breathability during use；
(2) manufacture method of three-dimensional fiber base is the simplest relative to the electrostatic spinning technique of tradition wound surface film, is easily controlled, nothing
Discuss raw material or process costs is the cheapest, there is preferable breathable moisture permeability；
(3) Wound dressing that the present invention manufactures, it is possible to promote dermal fibroblasts growth, accelerates the healing of injured skin, relatively
For hospital gauze, the required days minus that animal skin heals completely is a half left and right, and it is red and swollen not have wound surface
And cicatricial contracture.
Detailed description of the invention
Embodiment 1:
(1) three-dimensional fiber sill is manufactured
The first step: be dispersed in water by vinal, forms homogeneous suspension；In described suspension, the quality of fiber is divided
Number is 7%；Second step: described suspension carries out at 15 DEG C ripening 8h, makes suspension form coagulated mass；3rd step: adopt
Remove water or the ethanol of solidification in described coagulated mass with supercritical drying drying method, form fiber and interlock material；4th step: by fiber
Staggered material carries out 5h thermal crosslinking treatment, it is thus achieved that the three-dimensional fiber sill that fiber cross-point is adhesively fixed；
(2) porous process is carried out
The three-dimensional fiber sill that step (1) obtains is immersed in water, then adds cause porous combination thing, treatment temperature 25
DEG C, the time is 18min.
Described cause porous combination thing is: magnesium carbonate, foaming agent and biocompatible adhesive, wherein said foaming agent comprises phosphorus
The mol ratio that hydrochlorate and hydrophosphate, this phosphate and hydrophosphate exist in described compositions is 1:7, and said composition is hydrated
Shi Fanying thus produce as the carbon dioxide of gas component, wherein discharge described gas component in combination from described compositions
Thing produces the porosity of at least 8%；
(3) dipping collagen protein
The three-dimensional fiber sill dipping after porous the being processed collagen protein hydrosol containing cell growth factor, then does
Dry, cell growth factor content is 5wt%, and the content of collagen protein is 1300IU/mL；
(4) crosslinking curing
Carrying out crosslinking curing after Gan Zaoing, wherein, described cross-linking agent is diglycidyl ether of ethylene glycol, after crosslinking curing terminates,
Obtain wound repair dressing.
Wound repair dressing is bonded in fibrous base layer.
Embodiment 2:
(1) three-dimensional fiber sill is manufactured
The first step: be dispersed in by wire protein fiber in water or ethanol, forms homogeneous suspension；In described suspension, the matter of fiber
Amount mark is 7%；Second step: described suspension carries out at 15 DEG C ripening 8h, makes suspension form coagulated mass；3rd
Step: use supercritical drying drying method to remove water or the ethanol of solidification in described coagulated mass, forms fiber and interlocks material；4th step:
The material that interlocked by fiber carries out 2h thermal crosslinking treatment, it is thus achieved that the three-dimensional fiber sill that fiber cross-point is adhesively fixed；
(2) porous process is carried out
The three-dimensional fiber sill that step (1) obtains is immersed in water, then adds cause porous combination thing, treatment temperature 20
DEG C, the time is 50min.
Described cause porous combination thing is: magnesium carbonate, foaming agent and biocompatible adhesive, wherein said foaming agent comprises phosphorus
The mol ratio that hydrochlorate and hydrophosphate, this phosphate and hydrophosphate exist in described compositions is 1:6, and said composition is hydrated
Shi Fanying thus produce as the carbon dioxide of gas component, wherein discharge described gas component in combination from described compositions
Thing produces the porosity of at least 8%；
(3) dipping collagen protein
The three-dimensional fiber sill dipping after porous the being processed collagen protein containing basic fibroblast growth factor is water-soluble
Glue, is then dried, and basic fibroblast growth factor content is 8wt%, and the content of collagen protein is 130IU/mL；
(4) crosslinking curing
Carrying out crosslinking curing after Gan Zaoing, wherein, described cross-linking agent is dialdehyde starch, after crosslinking curing terminates, obtains wound surface
Repair dressing.In wherein said cross-linking agent solution, the content concn of cross-linking agent is 0.03mol/L；The time of described crosslinking curing
It is 8～9h.
Wound repair dressing is bonded in fibrous base layer.
Comparative example 1:
1) RGD recombinant spider silk protein-polyvinyl alcohol composite fiber film is prepared
RGD recombinant spider silk protein (Ji'nan University's offer) and polyvinyl alcohol (average degree of polymerization is 2400～2500) are dissolved in
In the formic acid solution of 98wt%, it is configured to containing 5wt%RGD recombinant spider silk protein and the spinning liquid of 5wt% polyvinyl alcohol.Spinning
Silk liquid suck 2mL specification syringe in, utilize electrostatic textile technology, 80kV (voltage strength), 20cm (syringe needle away from
Collect screen surfaces), 5ml/h (spinning liquid flow), under the conditions of 45 DEG C, spinning liquid is prepared as RGD recombinant spider silk protein-polyethylene
Alcohol composite cellulosic membrane.
2) preparation bFGF-collagen solution
Collagen protein (offer of bio tech ltd of Xu Er U.S., Shijiazhuang) is dissolved in sterilized water the collagen being configured to 2wt%
Protein solution, adds bFGF (offer of Ke Xin bio tech ltd, Beijing) by 500IU/ml, obtains bFGF-collagen protein molten
Liquid.
3) wound repair dressing is prepared
Above-mentioned prepared RGD recombinant spider silk protein-polyvinyl alcohol composite fiber film constant temperature 37 DEG C is immersed in above-mentioned prepared
30min in bFGF-collagen solution, is then placed in room temperature nature gel drying 2h in gel mold, obtains drying and moulding
Composite cellulosic membrane.
The composite cellulosic membrane of drying and moulding is put into crosslinking 8h in the EDC HCl solution that concentration is 0.01～0.05mol/L
Reinforce, obtain the wound repair dressing that thickness is 0.05mm.
Finally aseptic package bag is put in prepared wound repair dressing, carry out ethylene oxide sterilizing.Wound repair is applied
Material is bonded in fibrous base layer.
Comparative example 2:
Do not carry out step (2) porous to process, other steps embodiment 1 simultaneously
Comparative example 3:
(1) three-dimensional fiber sill is manufactured
The first step: be dispersed in by polylactic acid in water or ethanol, forms homogeneous suspension；In described suspension, the quality of fiber is divided
Number is 13%；Second step: described suspension carries out at 40 DEG C ripening 20h, makes suspension form coagulated mass；3rd step:
Use supercritical drying drying method to remove water or the ethanol of solidification in described coagulated mass, form fiber and interlock material；4th step: by fibre
The staggered material of dimension carries out 6h thermal crosslinking treatment, it is thus achieved that the three-dimensional fiber sill that fiber cross-point is adhesively fixed；
(2) porous process is carried out
The three-dimensional fiber sill that step (1) obtains is immersed in water, then adds cause porous combination thing, treatment temperature 15
DEG C, the time is 9min.
Described cause porous combination thing is: magnesium carbonate, foaming agent and biocompatible adhesive, wherein said foaming agent comprises phosphorus
The mol ratio that hydrochlorate and hydrophosphate, this phosphate and hydrophosphate exist in described compositions is 1:16；
(3) dipping collagen protein
The three-dimensional fiber sill dipping after porous the being processed collagen protein hydrosol containing cell growth factor, then does
Dry, cell growth factor content is 15wt%, and the content of collagen protein is 100IU/mL；
(4) crosslinking curing
Carrying out crosslinking curing after Gan Zaoing, wherein, described cross-linking agent is selected from 1-ethyl-3-(3-DimethylAminopropyl)-carbonization
Diimine, after crosslinking curing terminates, obtains wound repair dressing.In wherein said cross-linking agent solution, the content concn of cross-linking agent is excellent
Elect 0.08mol/L as, the time 14h of described crosslinking curing.
Wound repair dressing is bonded in fibrous base layer.
Wound repair dressing is in the test of wound surface
Test with 100 white rabbits, set up wounds in animals model, be randomly divided into 5 groups: embodiment 1 group, embodiment 2 groups, embodiment
3 groups, comparative example group and blank group, often group 20.After white rabbit anesthesia sterilization, it is manufactured into the otch of 3cm × 3cm, completely goes
Allowance for bark skin holostrome, paste flap coverage, blank wound surface by the embodiment group and comparative example group film with wound surface formed objects respectively
Do not do special handling, then sterile pressurized wrapping.Postoperative intramuscular injection penicillin 10u/kgbw, every day 2 times, injects for three days on end, prevention
Infect.Change dressings weekly, remove each group of film patch, wrap up by former method after wound clean.Each treated animal wound surface is observed after 1 to 4 week
Change, calculating Wound healing rate, Wound healing rate=(original wound surface area-existing wound surface area)/original wound surface area ×
100%, result such as table 1 below:
The Wound healing rate (%) that the postoperative different time points of table 1 is respectively organized
| Group | First week | Second week | 4th week |
| Blank | 14.91 | 63.33 | 98.94 |
| Comparative example 1 | 23.76 | 83.58 | 99.97 |
| Comparative example 2 | 25 | 79 | 98.88 |
| Comparative example 3 | 20 | 81 | 98.90 |
| Embodiment 1 | 27 | 90 | 99.99 |
| Embodiment 2 | 29 | 89 | 99.97 |
Table 1 shows the wound repair dressing that the second week healing rate of the present invention manufactures apparently higher than additive method.Embodiment group is created
Face has no clear scar contracture, nothing redness and inflammation, and blank group occurs that edema and inflammation, comparative example part have clear scar
Contracture.
The mensuration of porosity: under constant temperature, fills dehydrated alcohol in 5ml density bottle, and weigh (W1), by compound fibre
Dimension film weighs (Ws).And film is placed in density bottle, stand 15min, utilize vacuum pump to be de-gassed, until bubble-free effusion,
Making ethanol fully be diffused in the hole of film, fill it up with ethanol, weigh (W2).The sample being saturated with ethanol is taken out, to remaining second
Alcohol and density bottle carry out weigh (W3).Counting Formula: porosity=(W2-W3-Ws)/(W1-W3)
Table 2
| Porosity (%) | |
| Embodiment 1 | 88% |
| Embodiment 2 | 86% |
| Comparative example 1 | 82% |
| Comparative example 2 | 65% |
| Comparative example 3 | 83% |
Claims (6)
1. one kind without immunologic rejection adhesive bandage, it is characterised in that: adhesive bandage includes that fibrous base layer, adhesive layer and wound repair are applied
The bed of material.
2. the manufacture method of the adhesive bandage without immunologic rejection described in claim 1, it is characterised in that comprise the steps:
Manufacture three-dimensional fiber sill
The first step: be dispersed in by Biodegradable fibers in water or ethanol, forms homogeneous suspension；In described suspension, fiber
Mass fraction be 1-10%；Second step: described suspension is carried out at 15-36 DEG C ripening 8-15h, makes suspension shape
Become coagulated mass；3rd step: use supercritical drying drying method to remove water or the ethanol of solidification in described coagulated mass, form fiber and interlock
Material；4th step: the material that interlocked by fiber carries out 1-5h thermal crosslinking treatment, it is thus achieved that the three-dimensional fiber that fiber cross-point is adhesively fixed
Sill；
Biodegradable fibers is selected from: polylactic acid, polycaprolactone, PGA, polyurethane, polyvinyl alcohol or fibroin, elastic force
The fiber that one or more materials of the peptide polymer of albumen mimicry, alginic acid are made；
Carry out porous process
The three-dimensional fiber sill that step (1) obtains is immersed in water, then adds cause porous combination thing, treatment temperature 20
～60 DEG C, the time is 10～60min；
Described cause porous combination thing is: magnesium carbonate, foaming agent and biocompatible adhesive, wherein said foaming agent comprises phosphate
With the mol ratio that hydrophosphate, this phosphate and hydrophosphate exist in described compositions is 1:3-1:15, said composition water
React during conjunction thus produce the carbon dioxide as gas component, wherein discharge described gas component in group from described compositions
Compound produces the porosity of at least 8%；
(3) dipping collagen protein
The three-dimensional fiber sill dipping after porous the being processed collagen protein hydrosol containing cell growth factor, then does
Dry, cell growth factor content is 1-10wt%, and the content of collagen protein is 130 1500IU/mL；
(4) crosslinking curing
Carrying out crosslinking curing after Gan Zaoing, wherein, described cross-linking agent is selected from 1-ethyl-3-(3-DimethylAminopropyl)-carbonization
Diimine, glutaraldehyde, dialdehyde starch, diglycidyl ether of ethylene glycol, propanetriol-diglycidyl-ether, myrica extract, wattle extract,
Any one in 1,6-own diisocyanate；After crosslinking curing terminates, obtain wound repair dressing；
(5) adhesive bandage is manufactured
Wound repair dressing is bonded in fibrous base layer.
3. manufacture method as claimed in claim 2, in wherein said cross-linking agent solution, the content concn of cross-linking agent is preferably
0.01～0.05mol/L, more preferably 0.03mol/L；The time of described crosslinking curing be preferably 5～12h, more preferably 8～
9h。
4. manufacture method as claimed in claim 2, wherein said cytokine is to go back to the nest cell or chemotactic or cell divide
Changing the factor worked, these factors are selected from cell directional and migrate the factor (SDF-1), epidermal growth factor (EGF), become fiber
Cell growth factor (FGF), interleukin I L-3, angiogenin binding factor (ECM), transforminggrowthfactor-α (TGF-α),
Platelet-derived somatomedin (PDGF) or cell directional migrate the factor, insulin-like growth factor, bone morphogenetic protein, bone
Morphogenesis protein-2, VEGF, Connective Tissue Growth Factor, basic fibroblast growth factor, bone bridge
Albumen, growth hormones cytotaxis and adhesion factor.
5. manufacture method as claimed in claim 2, also includes in wherein said biocompatible adhesive: nucleic acid, carbon hydrate
Thing, protein, polypeptide, poly-('alpha '-hydroxy acids), poly-(lactone), poly-(aminoacid), poly-(anhydride), poly-(ortho esters), poly-(anhydride-
CO-acid imide), poly-(orthocarbonic ester), poly-(Alpha-hydroxy alkanoic acid ester), poly-(phosphate ester), poly-(L-lactide) (PLLA), poly-
(D, L-lactide) (PDLLA), PGA (PGA), poly-(lactide-CO-Acetic acid, hydroxy-, bimol. cyclic ester) (PLGA), poly-(L-lactide-
CO-D, L-lactide), poly-(D, L-lactide-CO-propylene carbonate), poly butyric ester (PHB), polycarboxylic acids, poly-(salt
Acid allylamine), poly-(chlorination diallyldimethyl ammonium), poly-(ethylenimine), poly-fumaric acid propylene glycol ester, polyvinyl alcohol, poly-
Vinyl pyrrolidone, polyethylene, polymethyl methacrylate, carbon fiber, Polyethylene Glycol, poly(ethylene oxide)polymers, poly-(vinyl
Alcohol), PVP, oxirane-CO-propylene oxide block copolymer, poly-(terephthalate
Ester), polyamide, and their copolymer.
6. manufacture method as claimed in claim 2, wherein said biocompatible adhesive is selected from: alginic acid, arabic acid, Guar
Glue, xanthan gum, gelatin, chitin, chitosan, acetic acid chitosan, lactic acid chitosan, chondroitin sulfate
Element, N, O-carboxymethylchitosan, glucosan, Fibrin Glue, glycerol, hyaluronic acid, hyaluronate sodium, cellulose,
Glycosamine, Dan Baiduotang proteoglycan PG, starch, lactic acid, PEO-PPO, sodium glycerophosphate, collagen, glycogen, angle egg
In vain, silk, and their mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610665180.4A CN106178063B (en) | 2016-08-14 | 2016-08-14 | A kind of no immunological rejection adhesive bandage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610665180.4A CN106178063B (en) | 2016-08-14 | 2016-08-14 | A kind of no immunological rejection adhesive bandage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106178063A true CN106178063A (en) | 2016-12-07 |
| CN106178063B CN106178063B (en) | 2019-09-27 |
Family
ID=57515228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610665180.4A Active CN106178063B (en) | 2016-08-14 | 2016-08-14 | A kind of no immunological rejection adhesive bandage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106178063B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107399119A (en) * | 2017-08-11 | 2017-11-28 | 恒天嘉华非织造有限公司 | A kind of high-end hygienic material of graphene-based fiber and its preparation technology |
| CN107744601A (en) * | 2017-09-06 | 2018-03-02 | 盐城工业职业技术学院 | A kind of 3 D-printing wound covering material based on silk microballoon bio-ink and preparation method thereof |
| CN108744027A (en) * | 2018-07-04 | 2018-11-06 | 长春工业大学 | A kind of protein-based liquid adhesive bandage and preparation method thereof |
| CN114748670A (en) * | 2022-04-11 | 2022-07-15 | 武汉诺薇生物科技有限公司 | Non-woven hemostatic gauze and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101420922A (en) * | 2005-12-06 | 2009-04-29 | 埃特克斯公司 | Porous calcium phosphate bone material |
| CN101822850A (en) * | 2009-03-06 | 2010-09-08 | 五邑大学 | Nano silver sterile bandage |
| CN103285424A (en) * | 2013-05-27 | 2013-09-11 | 东华大学 | Three-dimensional fiber-based aerogel tissue engineering scaffold and preparation method thereof |
| CN103550817A (en) * | 2013-10-29 | 2014-02-05 | 上海昌颌医药科技有限公司 | Bacterial cellulose/chitosan composite sponge dressing and preparation method thereof |
| CN204158771U (en) * | 2013-10-29 | 2015-02-18 | 上海昌颌医药科技有限公司 | A kind of Bacterial cellulose/chitosan composite sponge dressing |
-
2016
- 2016-08-14 CN CN201610665180.4A patent/CN106178063B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101420922A (en) * | 2005-12-06 | 2009-04-29 | 埃特克斯公司 | Porous calcium phosphate bone material |
| CN101822850A (en) * | 2009-03-06 | 2010-09-08 | 五邑大学 | Nano silver sterile bandage |
| CN103285424A (en) * | 2013-05-27 | 2013-09-11 | 东华大学 | Three-dimensional fiber-based aerogel tissue engineering scaffold and preparation method thereof |
| CN103550817A (en) * | 2013-10-29 | 2014-02-05 | 上海昌颌医药科技有限公司 | Bacterial cellulose/chitosan composite sponge dressing and preparation method thereof |
| CN204158771U (en) * | 2013-10-29 | 2015-02-18 | 上海昌颌医药科技有限公司 | A kind of Bacterial cellulose/chitosan composite sponge dressing |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107399119A (en) * | 2017-08-11 | 2017-11-28 | 恒天嘉华非织造有限公司 | A kind of high-end hygienic material of graphene-based fiber and its preparation technology |
| CN107744601A (en) * | 2017-09-06 | 2018-03-02 | 盐城工业职业技术学院 | A kind of 3 D-printing wound covering material based on silk microballoon bio-ink and preparation method thereof |
| CN107744601B (en) * | 2017-09-06 | 2020-09-25 | 盐城工业职业技术学院 | Three-dimensional printing wound coating material based on silk microsphere biological ink and preparation method thereof |
| CN108744027A (en) * | 2018-07-04 | 2018-11-06 | 长春工业大学 | A kind of protein-based liquid adhesive bandage and preparation method thereof |
| CN114748670A (en) * | 2022-04-11 | 2022-07-15 | 武汉诺薇生物科技有限公司 | Non-woven hemostatic gauze and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106178063B (en) | 2019-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106267315B (en) | A kind of wound repair dressing | |
| Kaur et al. | Biomaterials-based regenerative strategies for skin tissue wound healing | |
| Teixeira et al. | Recent advances in fiber–hydrogel composites for wound healing and drug delivery systems | |
| Sheokand et al. | Natural polymers used in the dressing materials for wound healing: Past, present and future | |
| Sultan et al. | Silk fibroin in wound healing process | |
| CN106178063B (en) | A kind of no immunological rejection adhesive bandage | |
| CN104013995B (en) | Oxidation chitosan graft modification pig dermis collagen micro-nano fiber film and preparation method thereof | |
| US20090092674A1 (en) | Flowable wound matrix and its preparation and use | |
| CN104857569A (en) | Preparation method of fibroin and graphene oxide composite bracket material | |
| CN109731130B (en) | Method for preparing hydrogel wound dressing by low-temperature biological 3D printing technology | |
| CN103041445A (en) | Method for preparing molecular imprinting porous gel membrane for tissue engineering | |
| US11529226B2 (en) | Artificial skin and a preparation method thereof | |
| CN113289050B (en) | Hemostatic sponge and preparation method thereof | |
| CN109381732A (en) | Electrostatic spinning dressing, preparation method and the application of growth factor-loaded micromolecular inhibitor | |
| CN110917386A (en) | Stem cell sponge scaffold, preparation method and application | |
| CN102228695A (en) | Method for preparing basic fibroblast growth factor sustained-release carrier | |
| KR102473363B1 (en) | Spray type hydrogel wound coating preparation method and Spray type hydrogel wound coating thereof | |
| CN107320768A (en) | Contain dressing of stem cell extract and preparation method thereof for wound repair | |
| CN114225113B (en) | Degradable artificial dura mater with double-layer structure and preparation method thereof | |
| Yaşayan et al. | Natural polymers for wound dressing applications | |
| Katiyar et al. | Novel strategies for designing regenerative skin products for accelerated wound healing | |
| CN108478852A (en) | A kind of pharmaceutical products, the carrier for loading pharmaceutical products, hydrogel and its method | |
| CN114917394B (en) | Double-layer nano-silver and growth factor-loaded composite functional dressing and preparation method thereof | |
| CN113481621B (en) | Wound hemostasis composite material, preparation method and application thereof | |
| Xiang et al. | Biological scaffold as potential platforms for stem cells: Current development and applications in wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190903 Address after: 273300 Shigu Community, Pingyi County Economic Development Zone, Linyi City, Shandong Province Applicant after: Shandong Furongtang Pharmaceutical Co., Ltd. Address before: 246702 Zongyang County in Anhui province Tongling City Yingbin Avenue North 14 Dragon Lake Bridge Liancheng Shengshi Building Room 502 Applicant before: Zhang Tianqi |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |